CH684740A5 - Absorptionsinhibitor für Verdauungs- und Zersetzungsprodukte von Nahrungsmitteln und Getränken. - Google Patents
Absorptionsinhibitor für Verdauungs- und Zersetzungsprodukte von Nahrungsmitteln und Getränken. Download PDFInfo
- Publication number
- CH684740A5 CH684740A5 CH3987/92A CH398792A CH684740A5 CH 684740 A5 CH684740 A5 CH 684740A5 CH 3987/92 A CH3987/92 A CH 3987/92A CH 398792 A CH398792 A CH 398792A CH 684740 A5 CH684740 A5 CH 684740A5
- Authority
- CH
- Switzerland
- Prior art keywords
- food
- absorption inhibitor
- agent
- inhibitor according
- decomposition products
- Prior art date
Links
- 235000013305 food Nutrition 0.000 title claims description 36
- 238000010521 absorption reaction Methods 0.000 title claims description 25
- 238000000354 decomposition reaction Methods 0.000 title claims description 22
- 239000003112 inhibitor Substances 0.000 title claims description 13
- 230000001079 digestive effect Effects 0.000 title description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 49
- 235000013361 beverage Nutrition 0.000 claims description 44
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 24
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 18
- 230000002378 acidificating effect Effects 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 206010010774 Constipation Diseases 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 235000020971 citrus fruits Nutrition 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 210000002784 stomach Anatomy 0.000 description 14
- 230000008859 change Effects 0.000 description 10
- 239000008187 granular material Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000000701 coagulant Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012055 enteric layer Substances 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 102000003914 Cholinesterases Human genes 0.000 description 3
- 108090000322 Cholinesterases Proteins 0.000 description 3
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 3
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940048961 cholinesterase Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 235000019631 acid taste sensations Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3359568A JPH05186357A (ja) | 1991-12-31 | 1991-12-31 | 飲食物消化分解産物吸収抑制手段 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH684740A5 true CH684740A5 (de) | 1994-12-15 |
Family
ID=18465171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH3987/92A CH684740A5 (de) | 1991-12-31 | 1992-12-30 | Absorptionsinhibitor für Verdauungs- und Zersetzungsprodukte von Nahrungsmitteln und Getränken. |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPH05186357A (enrdf_load_stackoverflow) |
| AU (1) | AU3045592A (enrdf_load_stackoverflow) |
| CA (1) | CA2086566A1 (enrdf_load_stackoverflow) |
| CH (1) | CH684740A5 (enrdf_load_stackoverflow) |
| DE (1) | DE4244588A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2685611B1 (enrdf_load_stackoverflow) |
| GB (1) | GB2262888B (enrdf_load_stackoverflow) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| ATE349214T1 (de) | 2001-09-08 | 2007-01-15 | Astrazeneca Ab | Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) * | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| AU2008202120B2 (en) * | 2003-04-05 | 2009-12-17 | Albireo Ab | Use of an IBAT inhibitor for the treatment of prophylaxis of constipation |
| US20130225511A1 (en) | 2010-11-04 | 2013-08-29 | Per-Göran Gillberg | Ibat inhibitors for the treatment of liver diseases |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| KR102811961B1 (ko) | 2018-06-20 | 2025-05-22 | 알비레오 에이비 | 오데빅시바트의 결정 변형물 |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| KR20210126053A (ko) | 2019-02-06 | 2021-10-19 | 알비레오 에이비 | 벤조티아디아제핀 화합물 및 담즙산 조절제로서의 그의 용도 |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761079B (zh) | 2019-12-04 | 2024-05-28 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| JP7665620B2 (ja) | 2019-12-04 | 2025-04-21 | アルビレオ・アクチボラグ | ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES3002777T3 (en) | 2020-08-03 | 2025-03-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| WO2022117778A1 (en) | 2020-12-04 | 2022-06-09 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2221139B1 (enrdf_load_stackoverflow) * | 1973-03-13 | 1978-03-24 | Nippon Kayaku Kk | |
| DE3307816A1 (de) * | 1983-03-02 | 1984-09-06 | Schering AG, 1000 Berlin und 4709 Bergkamen | Prostaglandin-haltiges pharmazeutisches praeparat und seine herstellung |
| GB8419245D0 (en) * | 1984-07-27 | 1984-08-30 | Reckitt & Colmann Prod Ltd | Medicinal compositions |
| JPS61172815A (ja) * | 1985-01-28 | 1986-08-04 | Toshiyuki Nakajima | 潤滑剤 |
| GB8817015D0 (en) * | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
| GB8910076D0 (en) * | 1989-05-03 | 1989-06-21 | Thackray C F Ltd | Sterilisable lubricant |
| JPH03120227A (ja) * | 1989-10-02 | 1991-05-22 | Shigeo Ochi | 飲食物消化分解産物吸収抑制剤 |
-
1991
- 1991-12-31 JP JP3359568A patent/JPH05186357A/ja active Pending
-
1992
- 1992-12-30 AU AU30455/92A patent/AU3045592A/en not_active Abandoned
- 1992-12-30 FR FR929215947A patent/FR2685611B1/fr not_active Expired - Fee Related
- 1992-12-30 GB GB9227128A patent/GB2262888B/en not_active Expired - Fee Related
- 1992-12-30 CH CH3987/92A patent/CH684740A5/de not_active IP Right Cessation
- 1992-12-31 CA CA002086566A patent/CA2086566A1/en not_active Abandoned
- 1992-12-31 DE DE4244588A patent/DE4244588A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE4244588A1 (enrdf_load_stackoverflow) | 1993-07-15 |
| JPH05186357A (ja) | 1993-07-27 |
| FR2685611B1 (fr) | 1994-06-10 |
| GB9227128D0 (en) | 1993-02-24 |
| CA2086566A1 (en) | 1993-07-01 |
| FR2685611A1 (fr) | 1993-07-02 |
| GB2262888B (en) | 1996-07-24 |
| AU3045592A (en) | 1993-07-08 |
| GB2262888A (en) | 1993-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH684740A5 (de) | Absorptionsinhibitor für Verdauungs- und Zersetzungsprodukte von Nahrungsmitteln und Getränken. | |
| DE69531900T2 (de) | Cerealien enthaltendes lebensmittel mit einem hohen gehalt an löslichen ballaststoffen | |
| DE60115094T2 (de) | Verwendung von zusammensetzungen zur verhütung oder linderung von syndromen mit multiplen risikofaktoren | |
| DE60220182T2 (de) | Alkoholfreies getränkeersatz | |
| DE69630694T2 (de) | Neutralisierung von sauren nahrungs- und arzneimitteln | |
| DE69031285T2 (de) | Bakteriumwachstumsfördernde Substanz enthaltend Pullulan mit oder ohne Dextran | |
| DE2919449B1 (de) | Diaetetisches Mittel zur natuerlichen Verdauungsregelung | |
| DE1617374A1 (de) | Verfahren zum Herstellen eines pharmazeutischen Praeparates mit verzoegerter Wirkung | |
| DE60132444T2 (de) | Behandlung von reizkolon-syndrom oder -krankheit | |
| DE60027303T2 (de) | Verfahren zur appetitzueglung | |
| DE69430580T2 (de) | Arzneimittel in nahrungsmittelform | |
| EP0484486A1 (de) | Lebensmittel mit prophylaktischer und/oder heilender wirkung und verfahren zu seiner herstellung. | |
| DE2821015A1 (de) | Diaetetisches praeparat | |
| DE3319575C2 (enrdf_load_stackoverflow) | ||
| DE60003556T2 (de) | Teilchenfoermige faserzusammensetzung | |
| DE10060750A1 (de) | Nahrungsergänzungsprodukt zur Darmaktivierung | |
| DE2944535A1 (de) | Diaetmittel, das zur verringerung des koerpergewichts und senkung des serumlipidspiegels geeignet ist, und verfahren zu seiner herstellung | |
| DE3139920A1 (de) | "mittel in granulatform auf basis von polysaccharid-gummen, verfahren zu seiner herstellung und verwendung" | |
| DE69232126T3 (de) | Aufnehmbare Zubereitungen enthaltend wasserlösliche, hochviskose Cellulosether | |
| DE69230590T2 (de) | Mittel gegen fettleibigkeit | |
| DE602004003173T2 (de) | Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung | |
| DE60220883T2 (de) | Lebensmittel für konstante Blutspiegel von Coffein und ihre Verwendung | |
| DE2845570A1 (de) | Honig enthaltende zusammensetzung | |
| DE69820527T2 (de) | Calciumkanalantagonist mit hemmender Wirkung auf die Freisetzung von Parathyroidhormonen und seine Verwendung | |
| CH715734A2 (de) | Probiotisches Nahrungsergänzungsmittel mit sekundären Pflanzenstoffen, hergestellt aus Kurkuma, Zimt, Pfeffer, Bienen Honig, Birnensaft Konzentrat, Speiseöl, Inulin und Hefe. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |